undamentalytics Newsletter
Sign in

Invivyd, Inc. income statement

In fiscal 2025, Invivyd, Inc. reported revenue of $53.4m, up 110.5% on the year before, operating income of −$55.6m (a -104.0% margin) and net income of −$52.5m, or −$0.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0255358
Research and development1591373878
Selling, general and administrative49636788
Operating income−213−177−56−113
Income tax0000
Net income−199−170−52−107
Diluted EPS−$1.81−$1.43−$0.30—
Diluted shares (average)110m119m172m—
EBITDA−212———

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FENC vs IVVDIVVD vs NTLAIVVD vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Invivyd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Invivyd, Inc.